))
Episode: 30 - Shining the Spotlight on Rare Disease Trials With Uncommon Cures
Manage episode 437901530 series 3335332
内容由Clinical Research News提供。所有播客内容（包括剧集、图形和播客描述）均由 Clinical Research News 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
This month’s episode of The Scope of Things features the latest trending news from host Deborah Borfitz, including a planned library of “nature’s drugs” targeting complex diseases, a paradoxical approach to treating cancer, how government policies can help improve equitable access to cancer trials, and the possibilities of reversing multiple sclerosis nerve damage. Marshall Summar, CEO of Uncommon Cures, and Tamanna Roshan Lal, Chief Medical Officer of Uncommon Cures, join the conversation to discuss how their organization is tackling the root causes of rare diseases trials that take too long and cost too much. They delve into the market interest behind rare disease trials and what Uncommon Cures is doing differently, as well as share the company’s international expansion plans and where they see this operationalized rare disease clinical trial paradigm in a few years.
SHOW NOTES
News Roundup
Pharmaceutical-grade HMOs
- Article in Clinical Research News
Paradoxical cancer treatment approach
Switching on the desire the exercise
- Study in Science Advances
STEP stroke platform trial
- Press release from the University of Cincinnati
Policy interventions to improve trial equity
New drug for MS
- Study in PNAS
Guests
CEO Marshall Summar, M.D., and CMO Tamanna Roshan Lal, M.D., with Uncommon Cures
- Article in Clinical Research News
The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider’s look at clinical research today.
33集单集
分享
